INSMED Inc 4

Chair and CEO William Lewis exercised options for 10,699 INSMED Inc. common shares and sold the same 10,699 shares in the open market for about $1.25 million under a 10b5-1 plan.

On July 9, 2026, INSMED Inc. Chair and CEO William Lewis exercised two tranches of stock options for a total of 10,699 shares of common stock (6,259 shares at a $30.46 strike and 4,440 shares at a $17.16 strike), then sold 10,699 shares of common stock in three open-market transactions at weighted average prices of $116.55, $117.62, and $118.52 per share pursuant to a Rule 10b5-1 trading plan adopted on September 4, 2025. The option exercises were reported at zero price in the Form 4 (standard for derivative-to-common conversions), but based on the reported sales prices, the gross value of the shares sold was approximately $1.25 million, suggesting this was a liquidity/monetization event rather than an incremental ownership increase. After these transactions, Lewis directly owned 259,058 shares of common stock and had an additional 233,924 shares held indirectly in a trust, with his post-transaction direct stake alone worth roughly $30 million using the contemporaneous sale prices.

Filing Facts

CIK

1104506

Ticker

INSM

Form

4

Source Type

fda

Accession

0001402051-26-000040

Alert Tier

7